Bird Flu News and Research

RSS

Flu vaccine shortages in developing countries could destabilize global security, says former WHO deputy head

"Flu vaccine shortages in developing nations may destabilize global security should the H1N1 [swine flu] virus become more deadly … David Heymann, a former deputy head of the World Health Organization" said Monday, Bloomberg reports.

10 Dec 2009

Expert advice for organ transplant surgeons on clinical issues posed by swine flu pandemic

Surgeons and other healthcare professionals specialising in solid organ transplants have been issued with expert advice to guide them through the complex clinical issues posed by the global H1N1 (swine flu) pandemic.

4 Dec 2009

NanoViricides announces filing of its quarterly report with the SEC

NanoViricides, Inc., reports that the Company has filed its quarterly report with the SEC on November 23rd.

30 Nov 2009

WHO investigates cases of H1N1 drug resistance in U.S., Britain

The WHO is looking into reports that patients with "severely suppressed immune systems" in Britain and the U.S. developed resistance Tamiflu, which is used to treat the symptoms of H1N1 (swine flu), a spokesman for the organization said Tuesday, Reuters reports.

25 Nov 2009

New FluCide better than the older version

NanoViricides, Inc., announced today that Dr. Eugene Seymour, MD MPH, CEO of the Company, presented lifetime data from the recent FluCide™ animal study on November 19th at the Influenza Congress USA 2009 in Washington, DC (www.terrapinn.com/usaflu). These data clearly established that the new version of FluCide™ is superior to the older version.

23 Nov 2009

Why avian flu virus has not caused a pandemic?

Bird flu viruses would have to make at least two simultaneous genetic mutations before they could be transmitted readily from human to human, according to research published today in PLoS ONE.

19 Nov 2009

NanoViricides to present data on its in vivo studies against influenza

NanoViricides, Inc., announced today that the Company’s CEO, Eugene Seymour, MD, MPH, has been invited to participate in a panel discussion at the Influenza Congress USA 2009, in Washington DC on November 19th (www.terrapinn.com/usaflu). The discussion will center on the “Evolving Role of Anti-Virals” in influenza treatment.

9 Nov 2009

SDC-based hard surface disinfectant is effective against the 2009 H1N1

PURE Bioscience, creators of the patented silver dihydrogen citrate (SDC) antimicrobial, announced today that its SDC-based hard surface disinfectant is effective against the 2009 H1N1 and is included on the list published by the U.S. Environmental Protection Agency (EPA) of antimicrobial products effective against the 2009 H1N1 flu strain based on their effectiveness against other influenza A virus strains.

27 Oct 2009

New anti-flu drugs to fight flu virus could become a reality

New anti-flu drugs could become a reality as a result of a study carried out by academics at the University of Hertfordshire.

27 Oct 2009

Anti-viral drug development programs progress successfully, reports NanoViricides

NanoViricides, Inc. (the "Company"), reports that the Company is well financed and its game changing anti-viral drug development programs are progressing successfully. As such, Management knows of no reason for the recent decline in stock price and associated volatility.

26 Oct 2009

Wildlife Conservation Society to monitor diseases for preventing global pandemic

The Wildlife Conservation Society will play a key role in a new international effort to monitor diseases that move between animals and people in order to prevent the next global pandemic.

24 Oct 2009

UC Davis' international effort to prevent new pandemics

In hopes of preventing the next global pandemic and a possible death toll into the millions, UC Davis today launches an unprecedented international effort to find and control diseases that move between wildlife and people.

24 Oct 2009

Aethlon Hemopurifier effective in capturing H1N1 Swine Flu Virus

Aethlon Medical, Inc. announced today that research studies have documented the Aethlon Hemopurifier® is effective in capturing the current pandemic strain of the H1N1 Swine Flu Virus. The Hemopurifier® is the first-in-class medical device able to selectively remove infectious viruses and immunosuppressive proteins from the bloodstream.

21 Oct 2009

Rice University scientists win NIH stimulus funds to study influenza A

Rice University scientists have won a $1.5 million grant from the National Institutes of Health to scrutinize the influenza A virus for clues that could lead to more effective antiviral drugs. Strains of influenza A include this year's pandemic H1N1 variety, some seasonal varieties and the much-feared H5N1 bird flu.

21 Oct 2009

Sinovac Biotech announces receipt of Panflu vaccine distribution approval in Hong Kong

Sinovac Biotech Ltd., a leading developer and provider of vaccines in China, announced today that its wholly-owned subsidiary, Sinovac Biotech (Hong Kong) Ltd, has received the Certificate of Approval to distribute Panflu(TM) (H5N1), its H5N1 (bird flu) pandemic influenza vaccine, in Hong Kong. The certificate is valid through September 13, 2014 and thereafter will be renewable for periods of five years at a time, subject to payment of the registration fee.

14 Oct 2009

NanoViricides completes a number of financing activities

NanoViricides, Inc. (the "Company"), announced today that it has completed a number of financing activities.

5 Oct 2009

The Replikin Count of H1N1 virus’s infectivity gene shows continued elevation

The latest H1N1 genomic data shows a 50% drop in the Replikin CountTM of the virus’s replikins lethality gene since its recorded highs in April 2009. In contrast, the Replikin Count of the virus’s infectivity gene showed a continued elevation.

30 Sep 2009

Aphios awarded NIH grant to develop pathogen inactivation technology for blood products

Aphios Corporation today announced that it has been awarded a RC-1 Challenge grant (No. 1RC1HL102822-01) from the National Heart, Lung, and Blood Institute (NHLBI), National Institute of Health’s (NIH) American Recovery and Reinvestment Act (ARRA) funds to develop a generally-applicable pathogen inactivation technology for blood products.

30 Sep 2009

Protection of front-line healthcare workers compromised

According to George Kappler, "If hospitals were subjected to the same protection standards as factories, many would have been shut down a long time ago." Those are tough words for healthcare workers to hear as they brace for an onslaught of H1N1 patients, but the CEO of Kappler, Inc., a 33-year veteran in the protective garment business, knows of what he speaks.

29 Sep 2009

Drug Discovery and Development to focus on pharmaceutical trends

NanoViricides, Inc., announced today that the Company’s CEO, Eugene Seymour, MD, MPH has been invited as a panelist at the 2nd Annual Livingston Healthcare Summit on September 24th, 2009 in New York City.

24 Sep 2009